Intermediate risk patients with grade 3 astrocytomas and CDKN2A/B hemizygous loss, intact CDKN2A/B but focal amplifications and grade 4 patients with intact CDKN2A/B and no focal amplifications have median OS of 80.4, 88.7 and 91.5 months, respectively. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).